The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.

In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.